Perpetua Medical

The distribution of the products has so far has been based on sales through two partners, B. Braun and Codonics. To increase exposure to customers, a broader approach is taken, with more distributors and partners.

The company's strategy has so far been based on sales of capital-intensive products with limited opportunities for recurring revenue. The new strategy assumes that the customer value lies in the analysis software and is based on the deployment of large volumes of simplified devices at a low price combined with a SaaS (Software as a Service) model for the analysis software. The customers can subscribe to the analyses they require and automatically benefit from continuous improvements and updated analysis software. By offering Pharmacolog's solutions at a lower entry cost, more hospitals can implement quality control of compounded drugs and thereby increase patient safety. The goal is also to create value for our shareholders. 

Erik Hedlund, acting CEO of Pharmacolog comments: "With the introduction of a SaaS strategy, the initial investment for hospitals can be reduced by up to 75% while the company secures recurring revenue. For its sales, the company has been dependent on the cooperation with the two companies B.  Braun and Codonics. The distribution network needs to be broadened with new partners and distributors in Europe, the US and Asia to ensure high growth."